A prospective observational study in Cystic Fibrosis Patients with chronic Pseudomonas aeruginosa infection treated with TOBI Podhaler (tobramycin inhalation power) or other FDA approved inhaled antipseudomonal antibacterial drug
An study for patients with cystic fibrosis (CF) treated with TOBI Podhaler or other FDA approved inhaled antipseudomonal antibacterial drug
Sponsor: Novartis
Enrolling: Male and Female Patients
IRB Number: AAAP9053
Contact: Yudy Fernandez-Pau: 212-305-6309 / yf2190@cumc.columbia.edu
Additional Study Information: This study is for patients who have been prescribed tobramycin inhalation powder (TOBI Podhaler) or another inhaled medication used to treat cystic fibrosis patients whose lungs contain bacteria called Pseudomonas aeruginosa. The purpose of this research study is to assess how well TOBI Podhaler works on treating Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis (CF).
This study is closed
Hossein Sadeghi, MD
Do You Qualify?
Have you been diagnosed with Cystic Fibrosis (CF)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Yudy Fernandez-Pau